Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

This study has been completed.
Brigham and Women's Hospital
Massachusetts General Hospital
Information provided by:
Dana-Farber Cancer Institute Identifier:
First received: August 24, 2005
Last updated: December 20, 2007
Last verified: December 2007
The purpose of this study is to determine if the combination of gemcitabine and vinorelbine is effective in treating patients with advanced soft tissue sarcoma.

Condition Intervention Phase
Sarcoma, Soft Tissue
Drug: gemcitabine
Drug: vinorelbine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study Evaluating Efficacy of the Combination of Gemcitabine and Vinorelbine in Advanced Soft Tissue Sarcoma

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To determine the response of the combination of gemcitabine and vinorelbine in patients with metastatic soft tissue sarcoma

Secondary Outcome Measures:
  • To determine the duration of response and the overall survival of patients with metastatic soft tissue sarcoma being treated with this combination
  • to evaluate the safety of this combination in this patient population

Estimated Enrollment: 40
Study Start Date: February 2003
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Patients will receive both gemcitabine and vinorelbine once a week for two weeks and then one week with no chemotherapy (1 cycle equals 21 days). Gemcitabine and vinorelbine will be administered on day 1 and day 8 of each cycle.

Blood tests will be performed on each day chemotherapy is administered. A CT scan will be done after every 2 cycles (approximately every 6 weeks) to determine the effects of the chemotherapy on the sarcoma.

A physical exam will be performed at the start of chemotherapy and at least every three weeks thereafter.

Patients will remain on this study as long as the disease does not progress or there are no unacceptable side effects.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic diagnosis of unresectable or metastatic soft tissue sarcoma
  • Measurable disease outside of a prior irradiated area
  • ECOG performance status 0,1, or 2.
  • 0 or 1 prior regimens for advanced disease.
  • Adequate end organ function, defined as bilirubin < 1.8; SGOT/SGPT < 2.5 x upper limit of normal (ULN); creatinine < 1.5 x ULN.
  • Negative pregnancy test
  • Life expectancy of greater than 3 months

Exclusion Criteria:

  • Patient has received any investigational agents within 28 days of first day of study drug dosing
  • Two or more prior regimens for advanced disease
  • Prior gemcitabine or vinorelbine
  • Another primary malignancy
  • Grade III/IV cardia dysfunction
  • Female patients who are pregnant or breast-feeding
  • Severe and/or life-threatening medical disease
  • Known diagnosis of HIV infection
  • Prior chemotherapy within 4 weeks prior to study entry
  • Major surgery within 2 weeks prior to study entry
  • Known hypersensitivity to either gemcitabine or vinorelbine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00134641

United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Principal Investigator: Suzanne George, MD Dana-Farber Cancer Institute
  More Information Identifier: NCT00134641     History of Changes
Other Study ID Numbers: 02-282
Study First Received: August 24, 2005
Last Updated: December 20, 2007

Keywords provided by Dana-Farber Cancer Institute:
soft tissue sarcoma
metastatic soft tissue sarcoma

Additional relevant MeSH terms:
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on May 25, 2017